Inloggen

Voer uw gebruikersnaam en wachtwoord hier in om in te loggen op de website:
Inloggen

Wachtwoord vergeten?

Please note: While some information will still be current in a year, other information may already be out of date in three months time. If you are in any doubt, please feel free to ask.

Symkevi

Vraag
Dear expert team,
what do you think, when will Symkevi be on the market in Germany? I read in some articles that it should be more efficient than Orkambi (2% more increasing of the lung function compared to Orkambi). Also the side effects seem to be markedly less.
Furthermore, if the combinations of 3 will enter the market sometime, one would be already on Symkevi (combination of 3 consists of Symkevi and another drug).
Do you habe any data? Are the first studies on the combination of 3 finished in January (clinicaltrials.org)?
Do you think one should change to Symkevi or go on taking Orkambi (thanks to Orkambi 10-12% more lung funciton)
Many thanks,
Antwoord
Hello,
Symkevi would be available earliest in the 4th quarter of 2018 in Germany, there is no exact timepoint, yet.
From the experience, it is better tolerated than Orkambi, probably also more effective concering FEV1 and exacerbations, therefore a change makes sense, if Orkambi was without or only with little effect or had side effects. You should decide this together with your treating physician in the center.
The phase 3 studies on the combination of 3 are still going on, the results have to be awaited for. The data from the phase 2 studies, however, are promising.
Best regards,
Dr. R. Fischer
26.10.2018